{
    "nct_id": "NCT03899259",
    "official_title": "A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata",
    "inclusion_criteria": "* Are at least 18 years and ≤60 years for males (≤70 years of age for females) at the time of informed consent.\n* Have severe or very severe AA, as determined by all of the following:\n\n  * Current AA episode of more than 6 months' duration and hair loss encompassing ≥50% of the scalp, as measured by SALT (AA-IGA of 3 or 4) at screening and baseline.\n  * No spontaneous improvement over the past 6 months.\n  * Current episode of severe or very severe AA of less than 8 years. Note: participants who have severe or very severe AA for ≥8 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years.\n* Male or nonpregnant, nonbreastfeeding female participants.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "* Primarily \"diffuse\" type of AA.\n* Are currently experiencing other forms of alopecia or any other concomitant conditions that would interfere with evaluations of the effect of study medication on AA.\n* Previously treated with an oral Janus kinase (JAK) inhibitor and had an inadequate response (for example, absence of significant terminal hair growth after at least 12 weeks of treatment).",
    "miscellaneous_criteria": ""
}